Showing 6291-6300 of 6808 results for "".
- Deepak Chadha is New Vice President of Regulatory Affairs for Suneva Medicalhttps://practicaldermatology.com/news/20140311-deepak_chadha_is_new_vicepresident_of_regulatory_affairs_for_suneva_medical/2459319/Suneva Medical appointed Deepak Chadha to Vice President of Regulatory Affairs. Chadha's role will be leading the development and implantation of regulatory practices. Chairman and Chief Executive Officer, Nicholas L. Teti, Jr. said, “Deepak has been responsible for several global regula
- Robert T. Kelley of Caliber Imaging & Diagnostics Named Vice President of US Saleshttps://practicaldermatology.com/news/20140305-robert_t_kelley_of_caliber_imaging__diagnostics_named_vice_president_of_us_sales/2459325/Caliber Imaging and Diagnostics has declared Robert T. Kelley vice president of US sales. Kelley, originally director of clinical sales since 2011, was due for a promotion. "We are delighted to promote Bob to Vice President of Sales, just as we were truly fortunate when he agreed to join
- Ellman to Launch PelleFirm at Annual Meeting of the AADhttps://practicaldermatology.com/news/20140227-ellman_to_launch_pellefirm_at_annual_meeting_of_the_aad/2459327/Ellman International, Inc., received FDA clearance to market its new PelleFirm RF Body Treatment System. The PelleFirm System is CE Marked for body skin tightening and cellulite reduction. In addition, it also has received FDA 510(K) clearance for tissue heating and the temporar
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr
- Promius Pharma, LLC Introduces Dr. Reddy's Authorized Generic Producthttps://practicaldermatology.com/news/20140225-promius_pharma_llc_introduces_dr_reddys__authorized_generic_product/2459331/Promius Pharma, LLC, launched its first Authorized Generic (AG) of Cloderm® Cream through its parent company Dr. Reddy's Laboratories on February 14. The AG is identical in formulation to Cloderm® Cream and will provide all the similar benefits, while increasing access and reducing pharmacy call
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n
- Onset Dermatologics Launches New Strength of Minocinhttps://practicaldermatology.com/news/20140225-onset_dermatologics_launches_new_strength_of_minocin/2459333/Onset Dermatologics launced a 75mg strength of Minocin (minocycline hydrochloride) Pellet-Filled Capsules, a tetracycline class antibiotic medicine used to treat infections caused by bacteria. Minocin may be used along with other agents in the treatment of severe acne.
- Video Intervention May Increase Skin Cancer Diagnosis in Older Menhttps://practicaldermatology.com/news/20140224-video_intervention_may_increase_skin_cancer_diagnosis_in_older_men/2459334/Showing men a video on skin self-examination and skin awareness may help to increase the number of patients who receive whole-body clinical skin examinations (CSEs) from their physicians, which could increase skin cancer diagnosis in older men, according to a study by Monika Jan
- DEKA Medical Receives FDA Clearance for the Synchro REPLA:Yhttps://practicaldermatology.com/news/20140213-deka_medical_receives_fda_clearance_for_the_synchro_replay/2459343/The FDA cleared DEKA Medical, Inc.'s Synchro REPLA:Y, an aesthetic workstation dedicated, but not limited, to high speed stable long-term, or permanent hair reduction, treatment of PFB, treatment of benign pigmented lesions, treatment of wrinkles and
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo